AIM2 and colorectal carcinoma: Patients with CRC are characterized by the genetic alteration/absence of AIM2 associated with an up to 3-fold increase in overall mortality and disease-specific mortality (HR = 3.14; 95% CI = 1.75–5.65) [23].